Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Department of Radiology and Medical Imaging, King Khalid University Hospital, Riyadh, Saudi Arabia.
J Nucl Med. 2018 Jan;59(1):89-92. doi: 10.2967/jnumed.117.192625. Epub 2017 Jul 26.
The objective of this study was to assess the impact of Ga-prostate-specific membrane antigen (Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Documented management plans before and after Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Management changed after Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results ( < 0.001) and higher prostate-specific antigen (PSA) levels ( = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive Ga-PSMA scan results, and higher PSA levels.
本研究旨在评估 Ga-前列腺特异性膜抗原（Ga-PSMA）PET/CT 对生化复发（BCR）患者前列腺癌管理的影响。回顾性分析了 100 例 BCR 患者 Ga-PSMA PET/CT 前后的记录管理计划，并记录了计划的变化。Ga-PSMA PET/CT 后 39 例患者（39%）的治疗方案发生了改变。在 68 例接受根治性前列腺切除术的患者中，有 23 例（33.8%）和 32 例先前接受根治性放疗的患者中，有 16 例（50%）发生了治疗方案改变。扫描阳性结果（<0.001）和较高的前列腺特异性抗原（PSA）水平（=0.024）与治疗方案改变有关。而 Gleason 分级、分期、转移性疾病的存在、PSA 速度或 PSA 倍增时间与治疗方案改变均无显著相关性。Ga-PSMA PET/CT 改变了 39%的 BCR 患者的管理策略，且在接受根治性放疗、Ga-PSMA 扫描阳性结果和较高 PSA 水平的患者中，改变更为常见。
